A phase I/II clinical trial with cell therapy treatment to significantly reduce the need for immune suppression treatment for both donor-matched and mismatched bone marrow transplant patients
Latest Information Update: 01 Dec 2015
At a glance
- Drugs Megadose drug combination Cell Source (Primary)
- Indications Bone marrow transplant rejection; Engraftment
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 11 Nov 2015 According to a company media release, Cell Source expects to use the same treatment protocol in this study that was used in the initial study conducted by the University of Parma (see CT profile 700263936).
- 12 Aug 2014 New trial record